Skip to main navigation Skip to search Skip to main content

Antifungal therapy in hematopoietic stem cell transplant recipients

  • Alessandro Busca*
  • , Livio Pagano
  • *Corresponding author
  • Azienda Ospedaliera - Universitaria Città della Salute e della Scienza di Torino

Research output: Contribution to journal › Article

Abstract

Invasive fungal infections (IFI) represent a major hindrance to the success of hematopoietic stem cell transplantation (HSCT), contributing substantially to morbidity and infection-related mortality. During the most recent years several reports indicate an overall increase of IFI among hematologic patients, in particular, invasive aspergillosis, that may be explained, at least partially, by the fact that diagnoses only suspected in the past, are now more easily established due to the application of serum biomarkers and early use of CT scan. Along with new diagnostic options, comes the recent development of novel antifungal agents that expanded the spectrum of activity over traditional treatments contributing to the successful management of fungal diseases. When introduced in 1959, Amphotericin B deoxycholate (d-AmB) was a life-saving drug, and the clinical experience over 50 years has proven that this compound is effective although toxic. Given the superior safety profile, lipid formulations of AmB have now replaced d-AmB in many circumstances. Similarly, echinocandins have been investigated as initial therapy for IA in several clinical trials including HSCT recipients, although the results were moderately disappointing leading to a lower grade of recommendation in the majority of published guidelines. Azoles represent the backbone of therapy for treating immunocompromised patients with IFI, including voriconazole and the newcomer isavuconazole; in addition, large studies support the use of mold-active azoles, namely voriconazole and posaconazole, as antifungal prophylaxis in HSCT recipients. The aim of the present review is to summarize the clinical application of antifungal agents most commonly employed in the treatment of IFI.
Original languageEnglish
Pages (from-to)e2016039-e2016045
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume8
Issue number1
DOIs
Publication statusPublished - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Hematology
  • Infectious Diseases

Keywords

  • Hematology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Antifungal therapy in hematopoietic stem cell transplant recipients'. Together they form a unique fingerprint.

Cite this